Loading patent…
AssigneeAmgen Inc.
InventorsYuan Cheng, Chawita Netirojjanakul, Jerry Ryan Holder, Bin Wu, James R. Falsey, Bradley J. Herberich, Kelvin Sham, Leslie P. Miranda, Shu-Chen Lu, Murielle M. Venient-Ellison, Shanaka Stanislaus, Junming Yie, Jing Xu
Estimating the term…
Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.
A method of treating a subject with a metabolic disorder, the method comprising administering to the subject a composition comprising a monoclonal human antibody that specifically binds to a polypeptide comprising the extracellular N-terminus of human Gastric Inhibitory Peptide Receptor (“GIPR”), wherein the antibody comprises a cysteine amino acid at one or more conjugation site(s);
Dependencies are inferred from the claim text.